The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.

Front Endocrinol (Lausanne) · 2026 · PMC13183531 · PMID 42165019

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Specifically, for IL-6, a highly significant reduction was noted, and for TNF-α, a significant decrease was also evident.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.